抄録
We previously assessed anti-lipidemic activity by evaluating lipoprotein profiles in PXB-cells®, human primary hepatocytes from humanized mice livers, using LipoSEARCH®. This highly sensitive assay system detects low levels of extracellular lipoproteins; however, an increased throughput is needed to simultaneously assay multiple analytes. We herein investigated whether an enzyme-linked immunosolvent assay (ELISA) on apolipoproteins (APO) accurately detects reductions in extracellular lipoprotein levels in PXB-cells treated with fenofibrate as an alternative to LipoSEARCH. These results suggest the applicability of ELISA on APO to the conventional screening of anti-lipidemic activities in a large number of candidates.